Anna focuses on the development and application of value-based pricing methods, as well as policies that foster rational and sustainable drug pricing.
Prior to joining MSKCC, Anna spent 10 years consulting on health economics and outcomes research, as well as pricing and market access for pharmaceutical and diagnostic products. An alumna of both Analysis Group and IMS Consulting Group, the scope of her work spans the US, EU5, and emerging economies. She has published numerous articles in peer-reviewed scientific and policy journals.
Anna holds bachelor’s and master’s degrees in economics from Tufts University.
Speaking : (2018) AstraZeneca